Companies › TOXR

TOXR 10-K & 10-Q changes, risk factors and insider trading

21Shares XRP ETF · CBOE · Commodity Contracts Brokers & Dealers · CIK 2028835 · All filings on SEC.gov

Everything below is quoted or computed from 21Shares XRP ETF's public SEC filings. It is not a recommendation to buy or sell. Automated comparisons can contain errors; confirm with the original filing.

At a glance

0Form 4 filings reporting open-market purchases (last 180 days)
0Form 4 filings reporting open-market sales (last 180 days)

Jump to: Annual report (10-K) · Quarterly report (10-Q) · Insider transactions · 13F holders

What changed in the latest 10-K

Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare (only one so far)..

What changed in the latest 10-Q

Comparing 10-Q filed 2026-08-11 (period ending 2026-06-30) with 10-Q filed 2026-05-13 (period ending 2026-03-31).

Risk Factors (10-Q Part II, Item 1A)

1new paragraphs
9removed paragraphs
0reworded paragraphs
1,652 → 61words in section

The section in the latest 10-Q reads in full:

There have been no material changes to the Risk Factors last reported under "Part I, Item 1A. Risk Factors” of the Trust’s Annual Report on Form 10-K for the period ended December 31, 2025 and under “Part II, Item 1A. Risk Factors” of the Trust’s Quarterly Report on Form 10-Q for the period ended March 31, 2026.

Removed heading “The Trust Agreement includes a provision restricting Shareholders’ right to bring a derivative action.”

Largest changes (selected automatically by length and topic keywords; quoted verbatim, no commentary)

Removed text topics: lawsuit, fine
“Under Section 7.4 of the Trust Agreement, Shareholders’ statutory right under Delaware law to bring a derivative action (i.e., to initiate a lawsuit in the name of the Trust in order to assert a claim belonging to the Trust against a fiduciary of the Trust or against a third-party when the Trust’s management has refused to do so) is restricted. …”
see in full comparison
Removed text
“The Trust Agreement includes a provision restricting Shareholders’ right to bring a derivative action.”
see in full comparison
Removed text topics: regulation
“These provisions apply to any derivative actions brought in the name of the Trust other than derivative claims brought under the federal U.S. securities laws and the rules and regulations thereunder. The enforceability of Section 7.04’s derivative action threshold and procedural requirements under applicable federal or state law has not been definitively established. …”
see in full comparison
Removed text
“In addition to the 10% ownership threshold described above, the Trust Agreement imposes the following further procedural conditions on any Shareholder seeking to bring a derivative action on behalf of the Trust: …”
see in full comparison
Removed text
“A Shareholder wishing to bring a derivative action on behalf of the Trust must satisfy both the 10% ownership threshold and the pre-suit demand process described above before commencing any such action, suit or other proceeding, further limiting the ability of a Shareholder to seek redress in the name of the Trust. …”
see in full comparison
Removed text
“Moreover, if Shareholders bringing a derivative action, suit or proceeding pursuant to this provision of the Trust Agreement do not hold 10% of the outstanding Shares on the date such an action, suit or proceeding is brought, or such Shareholders are unable to maintain Share ownership meeting the 10% threshold throughout the duration of the action, suit or proceeding, such Shareholders’ derivative action may be subject to dismissal. …”
see in full comparison
Full comparison: every changed paragraph (10)

Green = added, red = removed. Unchanged paragraphs and tables are not shown. Read the complete text in the original filing.

Added

There have been no material changes to the Risk Factors last reported under "Part I, Item 1A. Risk Factors” of the Trust’s Annual Report on Form 10-K for the period ended December 31, 2025 and under “Part II, Item 1A. Risk Factors” of the Trust’s Quarterly Report on Form 10-Q for the period ended March 31, 2026.

Removed

You should carefully consider the risk factors discussed below as well as the risk factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report, which could materially affect our business, financial condition or future results. Other than as described herein, there have been no material changes in our risk factors from those disclosed in our 2025 Annual Report on Form 10-K.

Removed

The risks described below and in our Annual Report are not the only risks facing the Trust. You should also consider any risks and uncertainties described under the caption “Risk Factors” in any applicable prospectus, prospectus supplement, registration statement or other document that we file with the SEC before or after the date of this prospectus that is incorporated by reference herein. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Removed

The Trust Agreement includes a provision restricting Shareholders’ right to bring a derivative action.

Removed

Under Section 7.4 of the Trust Agreement, Shareholders’ statutory right under Delaware law to bring a derivative action (i.e., to initiate a lawsuit in the name of the Trust in order to assert a claim belonging to the Trust against a fiduciary of the Trust or against a third-party when the Trust’s management has refused to do so) is restricted. Under Delaware law, a shareholder may bring a derivative action if the shareholder is a shareholder at the time the action is brought and either (i) was a shareholder at the time of the transaction at issue or (ii) acquired the status of shareholder by operation of law or the Trust’s governing instrument from a person who was a shareholder at the time of the transaction at issue. Additionally, Section 3816(e) of the Delaware Statutory Trust Act specifically provides that a “beneficial owner’s right to bring a derivative action may be subject to such additional standards and restrictions, if any, as are set forth in the governing instrument of the statutory trust, including, without limitation, the requirement that beneficial owners owning a specified beneficial interest in the statutory trust join in the bringing of the derivative action.” In addition to the requirements of applicable law and in accordance with Section 3816(e) of the Delaware Statutory Trust Act, the Trust Agreement provides that no Shareholder will have the right, power or authority to bring or maintain a derivative action, suit or other proceeding on behalf of the Trust unless two or more Shareholders who are eligible to bring such derivative action under the Delaware Trust Statute and who (i) are not “Affiliates” (as defined in the Trust Agreement and below) of one another and (ii) collectively hold at least 10% of the outstanding Shares join in the bringing or maintaining of such action, suit or other proceeding. “Affiliate” means (i) any Person directly or indirectly owning, controlling or holding with power to vote 10% or more of the outstanding voting securities of such Person, (ii) any Person 10% or more of whose outstanding voting securities are directly or indirectly owned, controlled or held with power to vote by such Person, (iii) any Person, directly or indirectly, controlling, controlled by or under common control of such Person, (iv) any employee, officer, director, member, manager or partner of such Person, or (v) if such Person is an employee, officer, director, member, manager or partner, any Person for which such Person acts in any such capacity; and “Person” means any natural person and any partnership, limited liability company, statutory trust, corporation, association, or other legal entity.

Removed

In addition to the 10% ownership threshold described above, the Trust Agreement imposes the following further procedural conditions on any Shareholder seeking to bring a derivative action on behalf of the Trust: (1) prior to bringing any such action, two or more non-affiliated Shareholders collectively holding at least 10% of the outstanding Shares must first make a pre-suit demand upon the Sponsor to bring the subject action, unless an effort to cause the Sponsor to bring such an action is not likely to succeed (a demand shall only be deemed not likely to succeed, and therefore excused, if the Sponsor has a personal financial interest in the transaction at issue, and the Sponsor shall not be deemed interested in a transaction or otherwise disqualified from ruling on the merits of a Shareholder demand by virtue of the fact that the Sponsor receives remuneration for his or her service as Sponsor of the Trust or as a trustee or director of one or more trusts that are under common management with or otherwise affiliated with the Trust); and (2) unless a demand is excused pursuant to clause (1) of this paragraph, the Sponsor must be afforded a reasonable amount of time to consider such Shareholder request and to investigate the basis of such claim and the Sponsor shall be entitled to retain counsel or other advisors in considering the merits of the request, and the Sponsor shall require an undertaking by the Shareholders making such request to reimburse the Trust for the expense of any such advisor in the event the Sponsor determines not to take action. Any decision by the Sponsor to bring, maintain, or compromise (or not to bring, maintain, or compromise) any such court action, proceeding or claim, or to submit the matter to a vote of Shareholders, shall be made by the Sponsor in good faith and shall be binding upon the Shareholders. In addition to claims that must be brought derivatively under applicable law, the Trust Agreement requires that any claim affecting all Shareholders of the Trust proportionately, based on their number of Shares of the Trust, must also be brought as a derivative claim subject to these conditions, regardless of whether such claim involves a violation of a Shareholder’s rights under the Trust Agreement or any other alleged violation of contractual or individual rights that might otherwise give rise to a direct claim (and regardless, in each case, of whether such claims sound in tort, fraud or otherwise, or are based on common law, statutory, equitable, legal or other grounds).

Removed

These provisions apply to any derivative actions brought in the name of the Trust other than derivative claims brought under the federal U.S. securities laws and the rules and regulations thereunder. The enforceability of Section 7.04’s derivative action threshold and procedural requirements under applicable federal or state law has not been definitively established. The 10% ownership threshold and procedural requirements represent contractual restrictions on derivative actions authorized by Section 3816(e) of the Delaware Statutory Trust Act, which expressly permits trust instruments to modify or restrict the rights of beneficial owners to bring derivative actions. However, the application of such a threshold in the context of a registered exchange-traded product has not been comprehensively addressed by the courts. Accordingly, it is possible that a court could decline to enforce the Trust’s 10% threshold and procedural requirements.

Removed

A Shareholder wishing to bring a derivative action on behalf of the Trust must satisfy both the 10% ownership threshold and the pre-suit demand process described above before commencing any such action, suit or other proceeding, further limiting the ability of a Shareholder to seek redress in the name of the Trust. Due to these additional requirements, a Shareholder attempting to bring or maintain a derivative action in the name of the Trust will be required to locate other Shareholders with which it is not affiliated and that have sufficient Shares to meet the 10% threshold based on the number of Shares outstanding on the date the claim is brought and thereafter throughout the duration of the action, suit or proceeding. Shareholders wishing to satisfy this ownership threshold would need to identify and coordinate with other Shareholders of the Trust. Because the Trust’s Shares are held in book-entry form through the DTC and beneficial ownership information is not publicly available, individual investors may face substantial difficulty in locating other Shareholders. There is no mechanism established by the Trust to facilitate such shareholder coordination, and the Trust is not required to assist Shareholders in identifying one another. Accordingly, even Shareholders who believe they have a legitimate derivative claim may, as a practical matter, be unable to satisfy the 10% threshold and bring an action. Even if successful, this may be difficult and may result in increased costs to a Shareholder attempting to seek redress in the name of the Trust in court.

Removed

Moreover, if Shareholders bringing a derivative action, suit or proceeding pursuant to this provision of the Trust Agreement do not hold 10% of the outstanding Shares on the date such an action, suit or proceeding is brought, or such Shareholders are unable to maintain Share ownership meeting the 10% threshold throughout the duration of the action, suit or proceeding, such Shareholders’ derivative action may be subject to dismissal. As a result, the Trust Agreement limits the likelihood that a Shareholder will be able to successfully assert a derivative action in the name of the Trust, even if such Shareholder believes that he or she has a valid derivative action, suit or other proceeding to bring on behalf of the Trust.

Removed

Because the Trust’s Shares are held in book-entry form through DTC, the beneficial owners of Shares are generally not reflected on the Trust’s share register. Accordingly, any shareholder or group of Shareholders seeking to establish that they collectively hold at least 10% of the outstanding Shares must provide documentary evidence of their beneficial ownership as of the date of the derivative demand. Acceptable evidence may include broker statements, DTC participant confirmations, account statements from a registered broker-dealer or bank that is a DTC participant, or such other documentation as the Trust may reasonably require.

Management's Discussion & Analysis (MD&A) (10-Q Part I, Item 2)

7new paragraphs
0removed paragraphs
13reworded paragraphs
2,113 → 2,706words in section

Largest changes (selected automatically by length and topic keywords; quoted verbatim, no commentary)

Reworded topics: litigation

Paragraph as it now reads, with added and removed wording marked:

The Trust issues Shares only in Creation Baskets of 10,000 or multiples thereof. Creation Baskets are issued and redeemed in exchange for cash.cash or in-kind for XRP. Individual Shares will not be redeemed by the Trust but are listed and traded on the Exchange under the ticker symbol “TOXR”. The Trust issues Shares in Creation Baskets on a continuous basis at the applicable NAV per Share on the creation order date The Trust pays the unitary Sponsor Fee of 0.30% of the Trust’s NAV. Prior to December 11, 2025, the Sponsor Fee was 2.50%. The Sponsor Fee is paid by the Trust to the Sponsor as compensation for services performed under the Trust Agreement. The Sponsor Fee accrues daily and is payable in XRP weekly in arrears. The Administrator calculates the Sponsor Fee on a daily basis by applying a 0.30% annualized rate to the Trust’s NAV, and the amount of XRP payable in respect of each daily accrual is determined by reference to the Pricing Benchmark. The Sponsor has agreed to pay all operating expenses (except for litigation expenses and other extraordinary expenses) out of the Sponsor Fee.date.
see in full comparison
New text topics: litigation
“The Trust pays the unitary Sponsor Fee of 0.30% of the Trust’s NAV. Prior to December 11, 2025, the Sponsor Fee was 2.50%. The Sponsor Fee is paid by the Trust to the Sponsor as compensation for services performed under the Trust Agreement. The Sponsor Fee accrues daily and is payable in XRP weekly in arrears. The Administrator calculates the Sponsor Fee on a daily basis by applying an annualized rate to the Trust’s NAV, and the amount of XRP payable in respect of each daily accrual is determined by reference to the Pricing Benchmark. …”
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

The Trust’s investment objective is to seek to track the performance of XRP, as measured by the performance of the Pricing Benchmark, adjusted for the Trust’s expenses and other liabilities. CF Benchmarks Ltd. is the Pricing Benchmark Provider. The Pricing Benchmark is designed to reflect the performance of XRP in U.S. dollars. In seeking to achieve its investment objective, the Trust holds XRP at its Custodians and the Administrator values its the Shares daily based on the Pricing Benchmark. The Trust is a passive investment vehicle and is not a leveraged product. The Sponsor does not actively manage the XRP held by the Trust. On June 30, 2026, the Sponsor provided notice to the Pricing Benchmark Provider of the termination, effective August 31, 2026, of the licensing agreement between the Sponsor and the Pricing Benchmark Provider relating to the use of the Pricing Benchmark. The Sponsor intends to enter into a licensing agreement with FTSE on or about August 24, 2026, whereby FTSE will provide each of the Sponsor, the Trust, and their affiliates a non-exclusive, non-transferable, non-sub-licensable, worldwide license to access, view and use FTSE index data to develop, create, calculate, settle, maintain or support and market the Trust. Accordingly, the change in pricing benchmark provider is not expected to have a material impact on the Trust's net asset value, the fair value measurement of the Trust's XRP, or the Trust's results of operations, and does not represent a change in accounting principle. The change will be applied prospectively from the date the successor benchmark becomes effective.
see in full comparison
New text
“Net decrease in net assets resulting from operations for the six months ended June 30, 2026 was $(85,241,051), consisting of a net change in unrealized depreciation on investment in XRP of $(71,524,810), a net realized loss of $(13,360,842) on XRP sold for redemptions, a net realized loss of $(127,552) on XRP sold to pay the Sponsor Fee, and a net investment loss of $(247,761), partially offset by a net realized gain of $19,495 on in-kind liabilities paid and a net change in unrealized appreciation on the Sponsor Fee payable of $419. …”
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

The Trust’s NAV decreased from $247,658,271 on December 31, 2025 to $142,148,631 on March 31, 2026 to $112,916,689 on June 30, 2026, a 42.60%20.56% decrease. The decrease inresulted the Trust’s NAV resulted primarily from a 26.47%22.37% decrease in the price of XRP, which fell from $1.83 on December 31, 2025 to $1.34$1.3436 on March 31, 2026.2026 Theto decrease in$1.0431 theon Trust’sJune NAV30, was2026, furtherpartially amplifiedoffset by a net decreaseincrease in Shares outstanding Shares, which fell from 13,890,000 on December 31, 2025 to 10,850,000 on March 31, 2026 to 11,110,000 on June 30, 2026, areflecting result of 990,000480,000 Shares (9948 Baskets) being created and 4,030,000220,000 Shares (40322 Baskets) beingredeemed redeemed during the quarter.
see in full comparison
Reworded

Paragraph as it now reads, with added and removed wording marked:

The Trust’s NAV increased from $209,352,190 on December 31, 2024 to $209,384,354 on March 31, 2025 to $225,184,821 on June 30, 2025, a 0.02%7.55% increase. The increase inresulted the Trust’s NAV resulted primarily from aan 0.74%8.22% increase in the price of XRP, which rose from $2.10 on December 31, 2024 to $2.11$2.1084 on March 31, 2025.2025 to $2.2818 on June 30, 2025, partially offset by the Sponsor Fee, which was charged at an annual rate of 2.50% of the Trust’s NAV during the period. No Shares were created or redeemed during the quarter.three months ended June 30, 2025, and the Shares were not listed on the Exchange during that period.
see in full comparison
Full comparison: every changed paragraph (20)

Green = added, red = removed. Unchanged paragraphs and tables are not shown. Read the complete text in the original filing.

Reworded

The Trust’s investment objective is to seek to track the performance of XRP, as measured by the performance of the Pricing Benchmark, adjusted for the Trust’s expenses and other liabilities. CF Benchmarks Ltd. is the Pricing Benchmark Provider. The Pricing Benchmark is designed to reflect the performance of XRP in U.S. dollars. In seeking to achieve its investment objective, the Trust holds XRP at its Custodians and the Administrator values its the Shares daily based on the Pricing Benchmark. The Trust is a passive investment vehicle and is not a leveraged product. The Sponsor does not actively manage the XRP held by the Trust. On June 30, 2026, the Sponsor provided notice to the Pricing Benchmark Provider of the termination, effective August 31, 2026, of the licensing agreement between the Sponsor and the Pricing Benchmark Provider relating to the use of the Pricing Benchmark. The Sponsor intends to enter into a licensing agreement with FTSE on or about August 24, 2026, whereby FTSE will provide each of the Sponsor, the Trust, and their affiliates a non-exclusive, non-transferable, non-sub-licensable, worldwide license to access, view and use FTSE index data to develop, create, calculate, settle, maintain or support and market the Trust. Accordingly, the change in pricing benchmark provider is not expected to have a material impact on the Trust's net asset value, the fair value measurement of the Trust's XRP, or the Trust's results of operations, and does not represent a change in accounting principle. The change will be applied prospectively from the date the successor benchmark becomes effective.

Reworded

The Trust issues Shares only in Creation Baskets of 10,000 or multiples thereof. Creation Baskets are issued and redeemed in exchange for cash.cash or in-kind for XRP. Individual Shares will not be redeemed by the Trust but are listed and traded on the Exchange under the ticker symbol “TOXR”. The Trust issues Shares in Creation Baskets on a continuous basis at the applicable NAV per Share on the creation order date The Trust pays the unitary Sponsor Fee of 0.30% of the Trust’s NAV. Prior to December 11, 2025, the Sponsor Fee was 2.50%. The Sponsor Fee is paid by the Trust to the Sponsor as compensation for services performed under the Trust Agreement. The Sponsor Fee accrues daily and is payable in XRP weekly in arrears. The Administrator calculates the Sponsor Fee on a daily basis by applying a 0.30% annualized rate to the Trust’s NAV, and the amount of XRP payable in respect of each daily accrual is determined by reference to the Pricing Benchmark. The Sponsor has agreed to pay all operating expenses (except for litigation expenses and other extraordinary expenses) out of the Sponsor Fee.date.

Added

The Trust pays the unitary Sponsor Fee of 0.30% of the Trust’s NAV. Prior to December 11, 2025, the Sponsor Fee was 2.50%. The Sponsor Fee is paid by the Trust to the Sponsor as compensation for services performed under the Trust Agreement. The Sponsor Fee accrues daily and is payable in XRP weekly in arrears. The Administrator calculates the Sponsor Fee on a daily basis by applying an annualized rate to the Trust’s NAV, and the amount of XRP payable in respect of each daily accrual is determined by reference to the Pricing Benchmark. The Sponsor has agreed to pay all operating expenses (except for litigation expenses and other extraordinary expenses) out of the Sponsor Fee.

Reworded

The NAV of the Trust is used by the Trust in its day-to-day operations to measure the net value of the Trust’s assets. The NAV is calculated on each day other than a day when the Exchange is closed for regular trading (a “Business Day”) and is equal to the aggregate value of the Trust’s assets less its liabilities based on the Pricing Benchmark. In determining the NAV of the Trust on any Business Day, the Administrator calculates the price of the XRP held by the Trust as of 4:00 p.m. ET on such day. The Administrator also calculates the “NAV per Share” of the Trust, which equals the NAV of the Trust divided by the number of outstanding Shares.

Reworded

In addition to calculating NAV and NAV per Share, for purposes of the Trust’s financial statements, the Trust determines the net asset value of the XRP market that the Trust considers its “principal market” as of 4:00 p.m. ETdetermined on thea valuationGAAP datebasis (the “Principal Market NAV”) and net asset value of the NAVTrust per Share of the XRP market that the Trust considers its “principal market” as of 4:00 p.m. ETdetermined on thea valuation dateGAAP basis (the “Principal Market NAV per Share”) on each valuation date for such financial statements. The determination of the Principal Market NAV and Principal Market NAV per Share is identical to the calculation of NAV and NAV per Share, respectively, except that the value of XRP is determined using the fair value of XRP based on the price in the XRP market that the Trust considers its “principal market” as of 4:00 p.m. ET on the valuation date, rather than using the Pricing Benchmark.

Reworded

NAV and NAV per Share are not measures calculated in accordance with GAAP and are not intended as substitutes for Principal Market NAV and Principal Market NAV per Share, respectively.

Reworded

For the Three Months Ended MarchJune 31,30, 2026

Reworded

The Trust’s NAV decreased from $247,658,271 on December 31, 2025 to $142,148,631 on March 31, 2026 to $112,916,689 on June 30, 2026, a 42.60%20.56% decrease. The decrease inresulted the Trust’s NAV resulted primarily from a 26.47%22.37% decrease in the price of XRP, which fell from $1.83 on December 31, 2025 to $1.34$1.3436 on March 31, 2026.2026 Theto decrease in$1.0431 theon Trust’sJune NAV30, was2026, furtherpartially amplifiedoffset by a net decreaseincrease in Shares outstanding Shares, which fell from 13,890,000 on December 31, 2025 to 10,850,000 on March 31, 2026 to 11,110,000 on June 30, 2026, areflecting result of 990,000480,000 Shares (9948 Baskets) being created and 4,030,000220,000 Shares (40322 Baskets) beingredeemed redeemed during the quarter.

Reworded

Net decrease in net assets resulting from operations for the three months ended MarchJune 31,30, 2026 was $(52,307,128),$32,933,923, resultingconsisting fromof a net change in unrealized depreciation on investment in XRP of $(40,434,40931,090,401), a net realized loss of $(11,683,9091,676,933) fromon XRP sold for redemptions, a net realized loss of $(63,15764,395) from on XRP sold to pay the Sponsor Fee, and a net investment loss of $(142,862104,899), and a net change in unrealized depreciation on the Sponsor Fee payable of $(318), partially offset by a net realized gain of $16,471$3,023 on in-kind liabilities paidpaid. andExcept a net change in unrealized appreciation on Sponsor Fee payable of $738. Other thanfor the Sponsor Fee of $142,862,$104,899, the Trust hadincurred no other expenses during the quarter.three months ended June 30, 2026.

Reworded

For the Three Months endedEnded onJune March 31,30, 2025

Reworded

The Trust’s NAV increased from $209,352,190 on December 31, 2024 to $209,384,354 on March 31, 2025 to $225,184,821 on June 30, 2025, a 0.02%7.55% increase. The increase inresulted the Trust’s NAV resulted primarily from aan 0.74%8.22% increase in the price of XRP, which rose from $2.10 on December 31, 2024 to $2.11$2.1084 on March 31, 2025.2025 to $2.2818 on June 30, 2025, partially offset by the Sponsor Fee, which was charged at an annual rate of 2.50% of the Trust’s NAV during the period. No Shares were created or redeemed during the quarter.three months ended June 30, 2025, and the Shares were not listed on the Exchange during that period.

Reworded

Net increase in net assets resulting from operations for the three months ended MarchJune 31,30, 2025 was $32,164,$15,800,467, resulting from a net change in unrealized appreciation on investment in XRPconsisting of $1,375,222, a net change in unrealized appreciation on Sponsorinvestment Feein payableXRP of $84,129,$17,188,651 and a net realized gain of $131,491$11,825 fromon XRP sold to pay the Sponsor Fee, partially offset by a net investment loss of $(1,558,6781,366,006) and a net change in unrealized depreciation on the Sponsor Fee payable of $(34,003). TheExcept Trust’s only expense during the quarter wasfor the Sponsor Fee of $1,558,678.$1,366,006, the Trust incurred no other expenses during the three months ended June 30, 2025.

Added

For the Six Months Ended June 30, 2026

Added

The Trust’s NAV decreased from $247,658,271 on December 31, 2025 to $112,916,689 on June 30, 2026, a 54.41% decrease. The decrease resulted primarily from a 42.91% decrease in the price of XRP, which fell from $1.8272 on December 31, 2025 to $1.0431 on June 30, 2026. The decline was further amplified by a net decrease in Shares outstanding, which fell from 13,890,000 on December 31, 2025 to 11,110,000 on June 30, 2026, reflecting 1,470,000 Shares (147 Baskets) created and 4,250,000 Shares (425 Baskets) redeemed during the period.

Added

Net decrease in net assets resulting from operations for the six months ended June 30, 2026 was $(85,241,051), consisting of a net change in unrealized depreciation on investment in XRP of $(71,524,810), a net realized loss of $(13,360,842) on XRP sold for redemptions, a net realized loss of $(127,552) on XRP sold to pay the Sponsor Fee, and a net investment loss of $(247,761), partially offset by a net realized gain of $19,495 on in-kind liabilities paid and a net change in unrealized appreciation on the Sponsor Fee payable of $419. Except for the Sponsor Fee of $247,761, the Trust incurred no other expenses during the six months ended June 30, 2026.

Added

For the Six Months Ended June 30, 2025

Added

The Trust’s NAV increased from $209,352,190 on December 31, 2024 to $225,184,821 on June 30, 2025, a 7.56% increase. The increase in the Trust’s NAV resulted primarily from an 8.91% increase in the price of XRP, which rose from $2.0951 on December 31, 2024 to $2.2818 on June 30, 2025, partially offset by the Sponsor Fee, which was charged at an annual rate of 2.50% of the Trust’s NAV during the period. No Shares were created or redeemed during the six months ended June 30, 2025, and the Shares were not listed on the Exchange during that period.

Added

Net increase in net assets resulting from operations for the six months ended June 30, 2025 was $15,832,631, consisting of a net change in unrealized appreciation on investment in XRP of $18,563,873, a net realized gain of $143,316 on XRP sold to pay the Sponsor Fee, and a net change in unrealized appreciation on the Sponsor Fee payable of $50,126, partially offset by a net investment loss of $(2,924,684). Except for the Sponsor Fee of $2,924,684, the Trust incurred no other expenses during the six months ended June 30, 2025.

Reworded

The Trust is not aware of any trends, demands, commitments, events, or uncertainties that are reasonably likely to result in material changes to its liquidity needs. The Trust’s only ordinary recurring expense is the fee paid to the Sponsor at an annual rate of 0.30% of the Trust’s total NAV.Fee. In exchange for the Sponsor Fee, the Sponsor has agreed to assume the ordinary fees and expenses incurred by the Trust, including but not limited to the following: fees charged by the Administrator, the Custodians, the Transfer Agent and the Trustee, the Marketing Fee, the Exchange’s listing fees, typical maintenance and transaction fees of the Depository Trust Company (“DTC”), SEC registration fees, printing and mailing costs, website fees, tax reporting fees, audit fees, license fees and expenses, up to $100,000 per annum in ordinary legal fees and expenses. The Sponsor bears expenses in connection with the Trust’s organization and initial offering costs.

Reworded

The Sponsor is not required to pay any extraordinary or non-routine expenses. Extraordinary expenses are fees and expenses which are unexpected or unusual in nature, such as legal claims and liabilities and litigation costs or indemnification or other unanticipated expenses. Extraordinary fees and expenses also include material expenses which are not currently anticipated obligations of the Trust. The Trust will be responsible for the payment of such expenses to the extent any such expenses are incurred. Routine operational, administrative, and other ordinary expenses are not deemed extraordinary expenses. The Trust will sell XRP on an as-needed basis to pay the Sponsor’sSponsor fee.Fee.

TOXR insider buying and selling (Form 4)

Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.

No Form 4 stock transactions in this period.

Well-known investors holding TOXR (13F)

None of the 59 investors we track reported a position in their latest 13F.

Coming soon: email alerts when TOXR files, watchlists and downloadable comparisons.